MP61-18 ELK-1 PROMOTES PROSTATE CANCER PROGRESSION AND SILODOSIN THAT INACTIVATES ELK-1 IN PROSTATE CANCER CELLS INCREASES SENSITIVITY TO GEMCITABINE

Autor:	Hiroshi Miyamoto, Takashi Kawahara, Eiji Kashiwagi, Hitoshi Ishiguro, Yichun Zheng, Ali Kadhim Aljarah, Yi Li
Rok vydání:	2015
Předmět:	Biochemical recurrence Oncology medicine.medical_specialty business.industry Prostatectomy animal diseases Urology medicine.medical_treatment Silodosin medicine.disease Gemcitabine Prostate cancer fluids and secretions Docetaxel DU145 Internal medicine Carcinoma medicine business medicine.drug
Zdroj:	Journal of Urology. 193
ISSN:	1527-3792 0022-5347
DOI:	10.1016/j.juro.2015.02.2199
Popis:	INTRODUCTION AND OBJECTIVES: LK-1 is a transcriptional factor whose phosphorylation is necessary for c-fos proto-oncogene activation. However, little is known about biological significance of ELK1 in prostate cancer. In addition, silodosin, a selective a1-adrenergic blocker used for the symptomatic treatment of benign prostatic hyperplasia, has been shown to decrease ELK-1 expression in human prostate smooth muscle cells. In this study, we aim to investigate the functions of ELK-1 in prostate cancer growth and the efficacy of silodosin, in combination with chemotherapeutic drugs, in cell proliferation. METHODS: We first immunohistochemically determined the levels of phospho-ELK-1 (pELK-1) expression in radical prostatectomy specimens. We then assessed the effects of ELK-1 knockdown via short hairpin RNA on cell proliferation, migration, and invasion as well as those of silodosin on ELK-1 expression/activity in prostate cancer lines and their viability. RESULTS: Immunohistochemistry showed that the levels of pELK-1 expression were significantly higher in carcinoma (positivity & score, P
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::4b5305a357ddf9ade77dce09dc80473b https://doi.org/10.1016/j.juro.2015.02.2199 Zobrazit plný text záznamu